EUVIMEDEUVIMED entdecken
Crossref

Evaluation of Tetrazine Tracers for Pretargeted Imaging within the Central Nervous System

Martin R Edelmann iD, Christoph Bredack, Sara Belli, Peter Mohr, Marie-Paule Imhoff, Flore Reggiani, Eric A Kusznir, Arne C Rufer, Daniel P Holt, Heather Valentine, Dean F Wong, Robert F Dannals und 2 weitere

Bioconjugate Chemistry · 2023

DOI: 10.1021/acs.bioconjchem.3c00385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2023. Verfasst von Martin R Edelmann und 13 weiteren Autor:innen. Beteiligte Einrichtung: Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Isotope Synthesis, F. Ho…. Hauptthemen laut MEDLINE: Heterocyclic Compounds. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pretargeting approach separates the biological half-life of an antibody from the physical half-life of the radioisotope label, providing a strategy for reducing the radiation burden. A widely explored pretargeting approach makes use of the bioorthogonal click reaction between tetrazines (Tzs) and trans-cyclooctenes (TCOs), combining the targeting specificity of monoclonal antibodies (mAbs) with the rapid clearance and precise reaction of Tzs and TCOs. Such a strategy can allow for the targeting and imaging (e.g., by positron emission tomography (PET)) of molecular markers, which cannot be addressed by solely relying on small molecules. Tz derivatives that undergo inverse electron-demand Diels-Alder (IEDDA) reactions with an antibody bearing TCO moieties have been investigated. This study describes the synthesis and characterization of 11 cold Tz imaging agent candidates. These molecules have the potential to be radiolabeled with 18F or 3H, and with the former label, they could be of use as imaging tracers for positron emission tomography studies. Selection was made using a multiparameter optimization score for the central nervous system (CNS) PET tracers. Novel tetrazines were tested for their pH-dependent chemical stability. Those which turned out to be stable in a pH range of 6.5-8 were further characterized in in vitro assays with regard to their passive permeability, microsomal stability, and P-glycoprotein transport. Furthermore, selected Tzs were examined for their systemic clearance and CNS penetration in a single-dose pharmacokinetic study in rats. Two tetrazines were successfully labeled with 18F, one of which showed brain penetration in a biodistribution study in mice. Another Tz was successfully tritium-labeled and used to demonstrate a bioorthogonal click reaction on a TCO-modified antibody. As a result, we identified one Tz as a potential fluorine-18-labeled CNS-PET agent and a second as a 3H-radioligand for an IEDDA-based reaction with a modified brain-penetrating antibody.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic CompoundsMiceRatsAnimalsTissue DistributionPositron-Emission TomographyAntibodies, MonoclonalRadiopharmaceuticalsCentral Nervous System

Substanzen

Heterocyclic CompoundsAntibodies, MonoclonalRadiopharmaceuticals

Autor:innen und Institutionen

  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Isotope Synthesis, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland.
  • Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, U.K.
  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Neuroscience and Rare Diseases, Discovery & Translational Medicine Area, Biomarker and Translational Technologies, F. Hoffmann-La Roche Ltd, Ba…
  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Pharmaceutical Science, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland.
  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland.
  • Roche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Lead Discovery, F. Hoffmann-La Roche Ltd, Basel CH-4070, Switzerland.

ORCID-Profile: Martin R Edelmann, Luca C Gobbi

Zitieren

APA

Edelmann, M. R., Bredack, C., Belli, S., Mohr, P., Imhoff, M. P., Reggiani, F., Kusznir, E. A., Rufer, A. C., Holt, D. P., Valentine, H., Wong, D. F., Dannals, R. F., Honer, M., & Gobbi, L. C. (2023). Evaluation of Tetrazine Tracers for Pretargeted Imaging within the Central Nervous System. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.3c00385

Vancouver

Edelmann MR, Bredack C, Belli S, Mohr P, Imhoff MP, Reggiani F, et al. Evaluation of Tetrazine Tracers for Pretargeted Imaging within the Central Nervous System. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.3c00385

BibTeX
@article{Edelmann2023,
  author = {Edelmann, Martin R and Bredack, Christoph and Belli, Sara and Mohr, Peter and Imhoff, Marie-Paule and Reggiani, Flore and Kusznir, Eric A and Rufer, Arne C and Holt, Daniel P and Valentine, Heather and Wong, Dean F and Dannals, Robert F and Honer, Michael and Gobbi, Luca C},
  title = {Evaluation of Tetrazine Tracers for Pretargeted Imaging within the Central Nervous System},
  journal = {Bioconjugate Chemistry},
  year = {2023},
  doi = {10.1021/acs.bioconjchem.3c00385}
}
Kostenlos starten →